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and Paula J. McKeown-Longo¶
From the Cell and Molecular Biology Program and the Department of Physiology and Cell Biology, Albany Medical
College, Albany, New York 12208 and the §Department of Experimental Pathology, Lund University, 22185 Lund, Sweden

The deposition of fibronectin into the extracellular matrix is
a dynamic, multistep process that is normally tightly regulated
in order to ensure controlled matrix deposition. In certain
disease states, including pulmonary fibrosis and atherosclerosis, loss of this regulation gives rise to either excess or inappropriate fibronectin deposition (1). In addition, reduced fibronectin deposition has been associated with altered
embryonic development, tumor cell invasion, and abnormal
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wound repair (1). The mechanisms that control the rate and
extent of fibronectin deposition are only partially understood.
Adherent cells polymerize an insoluble fibronectin matrix by
assembling cell- or plasma-derived soluble fibronectin into insoluble fibrils (2). In one of the initial steps of matrix assembly,
cell surfaces bind the amino-terminal region of fibronectin in a
reversible and saturable manner (3, 4). Subsequent homophilic
binding interactions are thought to promote the polymerization
of the fibronectin molecule into an insoluble matrix (5–9) and
allow for the regeneration of the cell surface amino-terminal
binding site (2). The binding of the amino terminus of fibronectin to cell surface receptors, termed matrix assembly sites (3),
is mediated by the first five type I repeats of fibronectin (4, 10).
The molecule(s) that mediates the binding of the amino terminus of fibronectin to cell surfaces has not been definitively
identified. It has been proposed that the III1 module of fibronectin (8, 11), large molecule mass molecules (12), and the
fibronectin-binding a5b1 integrin (13–15) interact with the
amino terminus of fibronectin on cell surfaces.
Expression of cell surface matrix assembly sites may be
rapidly up- and down-regulated by protein kinase C activation,
cyclic AMP levels, and 1-oleoyl lysophosphatidic acid (LPA)1
treatment (16 –18). Activators of protein kinase C, which effect
both stress fiber and focal contact formation (19), enhance
fibronectin matrix assembly (17). Conversely, increasing intracellular cAMP levels, which disrupt actin stress fibers and
cause cell retraction (20), inhibit matrix assembly (16). In addition, studies have demonstrated loss of matrix assembly sites
(21) and decreased fibronectin deposition (22) upon disruption
of the actin cytoskeleton with cytochalasin D. More recent
studies have defined a role for Rho-mediated contractility in
the expression of matrix assembly sites and fibronectin deposition (18, 23, 24). Increasing Rho-stimulated contraction
through treatment of cells with either LPA (18, 23) or nocodazole (24) or by microinjection of recombinant, constitutively
active Rho (23) results in an increase in amino-terminal fibronectin fragment binding and enhanced fibronectin deposition. Taken together, these observations indicate that matrix
assembly site expression and fibronectin deposition are regulated, in part, by actin stress fiber formation and the contractile
state of the cell.
Although it has been well documented that decreased fibronectin matrix assembly occurs in most transformed and
tumor-derived cell lines, little is known about the extracellular
signals that regulate matrix assembly activity in normal fibroblasts. Earlier studies have demonstrated that cells adherent
1
The abbreviations used are: LPA, 1-oleoyl lysophosphatidic acid;
GST, glutathionine S-transferase; DMEM, Dulbecco’s modified Eagle’s
medium; PCR, polymerase chain reaction; PBS, phosphate-buffered
saline; PMA, phorbol 12-myristate 13-acetate; FnIII, recombinant human fibronectin type III module; Vn, vitronectin.
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The deposition of fibronectin into the extracellular
matrix is an integrin-dependent, multistep process that
is tightly regulated in order to ensure controlled matrix
deposition. Reduced fibronectin deposition has been associated with altered embryonic development, tumor
cell invasion, and abnormal wound repair. In one of the
initial steps of fibronectin matrix assembly, the aminoterminal region of fibronectin binds to cell surface receptors, termed matrix assembly sites. The present
study was undertaken to investigate the role of extracellular signals in the regulation of fibronectin deposition. Our data indicate that the interaction of cells with
the extracellular glycoprotein, vitronectin, specifically
inhibits matrix assembly site expression and fibronectin
deposition. The region of vitronectin responsible for the
inhibition of fibronectin deposition was localized to the
heparin-binding domain. Vitronectin’s heparin-binding
domain inhibited both b1 and non-b1 integrin-dependent matrix assembly site expression and could be overcome by treatment of cells with lysophosphatidic acid,
an agent that promotes actin polymerization. The interaction of cells with the heparin-binding domain of
vitronectin resulted in changes in actin microfilament
organization and the subcellular distribution of the actin-associated proteins a-actinin and talin. These data
suggest a mechanism whereby the heparin-binding domain of vitronectin regulates the deposition of fibronectin into the extracellular matrix through alterations in
the organization of the actin cytoskeleton.
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EXPERIMENTAL PROCEDURES

Reagents and Antibodies—Gel electrophoresis supplies were from
Bio-Rad. Unless other indicated, chemicals were obtained from Sigma.
The polyclonal anti-fibronectin antibody was prepared by as described
previously (28). The following monoclonal antibodies were purchased:
anti-integrin avb3 (LM609), integrin subunit b5 (P1F6), a-actinin, and
talin from Chemicon International (Temecula, CA); anti-vinculin antibody from Sigma.
Cell Culture—Human foreskin fibroblasts, A1-Fs, were a gift from
Dr. Lynn Allen-Hoffmann (University of Wisconsin, Madison, WI).
A1-Fs were cultured in Dulbecco’s modified eagle’s medium (DMEM;
Life Technologies, Inc.) supplemented with 10% fetal bovine serum
(Sterile Systems, Logan, UT). GD25 and GD25b1 cells were cultured as
described previously (29).
Purification of Plasma Proteins and Fragments—Human plasma fibronectin was purified from a fibronectin- and fibrinogen-rich by-product
of Factor VIII production by ion exchange chromatography on DEAEcellulose (Amersham Pharmacia Biotech) as described previously (30).
The 70-kDa amino-terminal fragment of fibronectin was generated by
limited digestion of intact fibronectin with cathepsin D, followed by gelatin affinity chromatography as described previously (30).
Vitronectin was purified from fibronectin- and fibrinogen-depleted
human plasma by heparin-Sepharose (Amersham Pharmacia Biotech)
affinity chromatography according to the method of Yatohgo et al. (31).
The 40-kDa cell-binding fragment of vitronectin was generated by acid
cleavage of intact vitronectin (32). Purified vitronectin was dissolved in
70% formic acid and incubated at 37 °C for 46 h. The digested vitronectin was diluted 1:10 with water, lyophilized, and reconstituted in 50 mM
Tris, pH 7.6. The 40-kDa cell-binding fragment of vitronectin was
separated from heparin-binding fragments by exclusion on a heparinSepharose affinity column. Vitronectin fragments that bound to the
heparin-Sepharose were eluted with 0.5 M NaCl in 25 mM phosphate
buffer, pH 7.4. Both the cell-binding and heparin-binding fragments
were dialyzed extensively against PBS prior to use. Purity of protein
preparations was assessed by SDS-polyacrylamide gel electrophoresis,
and proteins were frozen at 280 °C until use.
Rat tail collagen type I was purchased from Beckton Dickinson.
Laminin (purified from EHS tumors) was purchased from Upstate
Biotechnology, Inc. (Lake Placid, NY). Thrombospondin was purified
from platelet releasate as described previously (72) and was a gift from
Dr. Deane Mosher (University of Wisconsin, Madison, WI). Fibrinogen
was purified from human plasma (33) and was a gift of Dr. John Kaplan
(Albany Medical College).
Purification of Recombinant Proteins—Recombinant human fibronectin III9,10 (FnIII9,10) was expressed in BL21 (DE3) bacteria as a
fusion protein with glutathione S-transferase (GST) as described previously (9). FnIII9,10 was separated from GST by digestion with trypsin
followed by chromatography over glutathione-agarose (9).
Polymerase chain reaction (PCR) was used to amplify human fibronectin cDNA encoding the 12th and 13th type III modules of fibronectin (FnIII12,13) (bases 5081–5623). This DNA encodes amino acids

Ala-1689 through Thr-1869, which represents the major heparin-binding region of fibronectin (34). Bases are numbered from the A in the
codon for the first amino acid of the mature protein (EMBL accession
number X02761), and amino acids are numbered from the aminoterminal pyroglutamic acid (35). PCR was also used to amplify human
vitronectin cDNA) encoding the heparin-binding domain of vitronectin
(VnHBD) (bases 1138 –1258) (36, 37). This DNA encodes amino acids
from Ala-341 through Ala-380 (38, 39). The sense primers for the
FnIII12,13 construct (59-CCGGATCCGCTATTCCTGCACCAACTGAC)
and the VnHBD construct (59-CCCGGATCCGCACCCCGCCCCTCCTTG) were synthesized with a BamHI site (shown in boldface type) at the
59-end. The antisense primers for the FnIII12,13 construct (59-CCCGAATTCCTATAGTGGAGGC GTCGATGACCA) and the VnHBD construct
(59-CCCGAATTCCTAGGCGCGGGATGGCCGGCG) were synthesized
with an EcoRi site (shown in boldface type) at the 59-end. Underlined
bases introduce a stop codon after the last base in the sequence to be
amplified. PCR was performed according to established procedures (40),
using human full-length fibronectin cDNA, pFH100 (a gift from Dr.
Jean Thiery, Paris, France) or vitronectin cDNA (a gift from Dr. Erkki
Ruoslahti, Burnham Institute, La Jolla, CA) as a template. Following
restriction enzyme digestion, the PCR-amplified DNA was cloned into
the bacterial expression vector pGEX-2T (Amersham Pharmacia Biotech) and transfected into BL21 (DE3) bacteria using standard procedures (40). PCR-amplified DNA was sequenced to confirm that no base
changes had been introduced during amplification of the DNA. Fusion
proteins were isolated by passing bacterial lysates over glutathioneagarose as described previously (8) and were dialyzed extensively
against PBS prior to use. Both GST-FnIII12,13 and GST-VnHBD bound
avidly to heparin-Sepharose (data not shown).
Recombinant vitronectins were produced using a baculovirus expression system. Nonmutant and mutant vitronectins were PCR-amplified
using the sense primer 59-GGCTACCGTTCACAACGA and the antisense primer 59-GGGTCTAGACTACAGATGGCCAGGAGCTGG. The
VnRGE mutant was produced using recombinant PCR (41). The two
mutagenic primers were 59-GCAAGCCCCAAGTGACTCGCGGGGAGGTGTTCACTATGCCGGAGGATGAGT (sense) and 59-ACTCATCCTCCGGCATAGTGAACACCTCCCCGCGAGTCACTTGGGGCTTGC (antisense). The mutated bases are shown in boldface type. The two outer
primers used were the same as those used to amplify nonmutant
vitronectin. PCR-amplified DNA was cloned into the baculovirus expression vector, PVL1392 (Pharmingen), using the restriction enzymes
NotI and XbaI.
Recombinant viruses were generated according to established procedures (42, 43). Viral stocks were prepared using SF21 cells grown in
serum-free SF900II medium (Life Technologies, Inc.). Supernatants
from infected cells were collected 72 h postinfection. To purify the
recombinant vitronectins, supernatants were treated with 8 M urea for
2 h at 20 °C and passed over columns of heparin-Sepharose (Amersham
Pharmacia Biotech). Resins were washed with 130 mM NaCl, 4 M urea
in 25 mM phosphate, pH 6.5, and bound proteins were eluted with 0.5 M
NaCl, 4 M urea in 50 mM phosphate buffer, pH 8. The recombinant
vitronectins were dialyzed extensively against PBS. Purity of the recombinant protein preparations was assessed by SDS-polyacrylamide
gel electrophoresis, and proteins were frozen at 280 °C until use.
Cell Binding Assays—The 70-kDa fibronectin fragment was iodinated with 1.0 mCi of Na125I (NEN Life Science Products) using chloramine T as described previously (3). Fibronectin, laminin, vitronectin,
thrombospondin, anti-integrin antibodies, and FnIII9,10 were diluted to
10 mg/ml in PBS and coated onto 24-well tissue plates (Corning/Costar)
for 3 h at 37 °C. Thrombospondin was reduced with 20 mM dithiothreitol
for 30 min at 20 °C prior to use (44). Fibrinogen was coated onto culture
plates at 100 mg/ml in PBS. Collagen was coated onto culture plates in
0.02 N acetic acid at 50 mg/ml at 4 °C overnight. Protein-coated wells
were washed three times with PBS before use. To minimize endogenous
fibronectin levels during experimental procedures, cells were washed
three times with serum-free DMEM and pretreated for 3.5 h with
cycloheximide (20 mg/ml) (30) in DMEM containing ITS12 (Sigma) as
described previously (15). Cells were seeded at 105 cells/well in DMEM/
ITS12 with 20 mg/ml cycloheximide. Following an overnight incubation, cells were washed three times with serum-free DMEM and incubated for 1 h with 0.5 3 106 cpm/ml 125I-labeled 70-kDa fragment (;20
ng/well) in DMEM containing 0.2% bovine serum albumin (45). Cell
adhesion was quantitated in parallel wells by staining with 0.5% crystal
violet as described previously (15).
Immunofluorescence Microscopy—For fibronectin matrix assembly
assays, non-cycloheximide-treated fibroblasts were seeded onto fibronectin-coated coverslips in 12-well cluster dishes at 105 cells/well in
DMEM/ITS12 in the absence or presence of 1.7 mM GST/VnHBD, GST/
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to vitronectin exhibit decreased levels of cell surface matrix
assembly sites compared with fibronectin-adherent cells (21,
25–27). These data suggest the possibility that the interaction
of cells with vitronectin generates inhibitory signals that regulate matrix assembly site expression. In the present study, we
demonstrate that the interaction of cells with vitronectin inhibits matrix assembly site expression and fibronectin deposition. The region of vitronectin responsible for the inhibition of
fibronectin matrix assembly was localized to the heparin-binding domain. The inhibitory effect of vitronectin’s heparin-binding domain was independent of the integrin receptor used to
assemble the fibronectin matrix. Vitronectin-mediated inhibition of matrix assembly site expression could be overcome by
treatment of cells with LPA, an agent that promotes actin
polymerization (18, 24). Moreover, the interaction of fibronectin-adherent cells with the heparin-binding domain of vitronectin resulted in changes in actin microfilament organization and
the subcellular distribution of the actin-associated proteins,
a-actinin, and talin. These data suggest a mechanism whereby
the heparin-binding domain of vitronectin down-regulates fibronectin matrix assembly through alterations in the organization of the actin cytoskeleton.
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FnIII12,13, or 0.75 mM recombinant vitronectin and incubated overnight
at 37 °C. Cells were fixed and permeabilized, and fibronectin fibrils
were visualized using a polyclonal anti-fibronectin antibody followed by
a fluorescein isothiocyanate-conjugated goat anti-rabbit antibody (Cappel). Cells were examined using an Olympus BX60 microscope equipped
with epifluorescence and photographed using a spot digital camera
(Diagnostic Instruments, Sterling Heights, MI).
To assay changes in actin distribution, confluent fibroblasts were
washed with serum-free media and incubated overnight in serum-free
DMEM. Cells were detached with trypsin/EDTA, washed, and seeded
onto fibronectin coverslips in 12-well cluster dishes at 1.5 3 104 cells/
well in DMEM/ITS12 in the absence or presence of 3.4 mM of GST/
VnHBD, GST/FnIII12,13, or GST. Following an overnight incubation at
37 °C, actin filaments were visualized by staining fixed and permeabilized cells with fluorescein isothiocyanate-phalloidin (Molecular Probes,
Inc., Eugene, OR). Vinculin was visualized using an anti-vinculin antibody (Sigma) followed by a Texas Red-conjugated goat anti-mouse
secondary antibody (Cappel).
Cellular Localization of Actin-associated Proteins—To assay changes
in the cellular distribution of a-actinin, talin, and vinculin, serumstarved, non-cycloheximide-treated fibroblast cells were fractionated
into digitonin-soluble and -insoluble (cytoskeletal-associated) fractions
(46). Cells were seeded at 4 3 105 cell/well into fibronectin-coated
six-well tissue culture plates in the absence or presence of 1.7 3 1026 M
GST/VnHBD or GST/FnIII12,13. Following an overnight incubation at
37 °C, cells were washed three times with cold PBS and incubated for 5
min on ice with 0.1% digitonin in 50 mM Hepes, pH 6.9, containing 1 mM
MgCl2, 1 mM EDTA, 1 mM EDTA, and inhibitors (10 mM sodium pyrophosphate, 50 mM sodium fluoride, 25 mM b-glycerophosphate, 25 mg/ml
leupeptin, 25 mg/ml aprotinin, 0.5 mM sodium orthovanadate, 1 mM
H2O2, 0.5 mg/ml soybean trypsin inhibitor, and 2 mM phenylmethylsulfonyl fluoride). Following removal of the digitonin-soluble fractions,
cells were washed two times with PBS and incubated on ice with
radioimmune precipitation buffer (1% Triton X-100, 0.1% SDS, 1%
sodium deoxycholate in 50 mM Tris, pH 7.6, with 150 mM NaCl and
inhibitors). Lysates were clarified by centrifugation at 15,000 3 g for 10
min at 4 °C. Supernatants were assayed for protein concentration using
bicinchroninic acid (BCA) reagents (Pierce) according to the manufacturer’s instructions. Samples (10 mg) were analyzed under nonreducing
conditions by SDS-polyacrylamide gel electrophoresis and immunoblotting as described previously (8). Immunoblots were developed using
enhanced chemiluminescence (Amersham Pharmacia Biotech) according to the manufacturer’s protocol.
RESULTS

Effect of Adhesive Substrates on Matrix Assembly Site Expression—The polymerization of a fibronectin matrix is a celldependent process that is regulated by the expression of specific matrix assembly sites on the surface of substrate-attached
cells (2). These sites have been identified by radioligand binding assays using either 125I-labeled 70-kDa or 125I-labeled 27kDa fragments derived from the amino terminus of fibronectin
(3, 4). Previous studies have demonstrated that cells adherent
to vitronectin do not express matrix assembly sites (21, 25, 26).
To examine further the effect of extracellular matrix molecules
on the expression of matrix assembly sites, cycloheximide-pretreated fibroblasts were allowed to adhere and spread on tissue
culture wells coated with various adhesive proteins. Matrix
assembly site expression on these cells was then measured in a
1-h binding assay using 125I-labeled 70-kDa fragment. Previous
studies have identified a homophilic binding site for the amino
terminus of fibronectin within the III1 module (8, 11). Therefore, fibroblasts were also seeded onto the RGD-containing
III9,10 modules of fibronectin, which mediate cell adhesion (9)
but do not contain III1. As shown in Fig. 1A, cells adherent to
vitronectin bound significantly less 125I-labeled 70-kDa fragment than cells adherent to either laminin, fibronectin,
FnIII9,10, collagen, thrombospondin, or fibrinogen. These results suggest that among these adhesive proteins, vitronectin
is distinct in its ability to down-regulate matrix assembly sites.
Previous studies have shown that the expression of matrix
assembly sites on fibroblast monolayers is rapidly up-regulated
either by activation of protein kinase C with phorbol esters (47)

FIG. 1. Effect of adhesive substrates on 70-kDa binding site
expression. A, cycloheximide-pretreated fibroblasts were seeded onto
tissue culture wells precoated with vitronectin (Vn), laminin (Ln), fibronectin (Fn), recombinant III9 and III10 modules of fibronectin
(FNIII9,10), collagen (Col), thrombospondin (Tsp), or fibrinogen (Fg) as
described under “Experimental Procedures.” Cells were allowed to adhere and spread for 15 h at 37 °C. 125I-Labeled 70-kDa fragment binding assays were performed as described under “Experimental Procedures.” Similar numbers of cells adhered to each substrate as assessed
by staining parallel wells with crystal violet (data not shown). B, cells
were seeded onto vitronectin (Vn) or FNIII9,10 and left untreated
(1PBS) or incubated with 100 nM PMA (1PMA) or 2 mM LPA (1LPA)
for 1 h prior to assay. Data are presented as the amount of 125I-labeled
70-kDa fragment bound per well 6 S.E. and represent one of three
experiments done in triplicate.

or by increasing Rho-stimulated contractility through treatment with either LPA (18, 23) or nocodazole (24). To determine
whether matrix assembly site expression on vitronectin-adherent cells could be similarly increased, cycloheximide-pretreated, vitronectin-adherent cells were incubated with either
PMA or LPA for 1 h, and the level of 125I-labeled 70-kDa
fragment binding was assessed. Treatment of vitronectin-adherent cells with 2 mM LPA resulted in a 2-fold increase in
125
I-labeled 70-kDa fragment binding to levels similar to that
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observed on cells adherent to FnIII9,10 (Fig. 1B). In contrast,
treatment of vitronectin-adherent cells with PMA had no affect
on 125I-labeled 70-kDa fragment binding (Fig. 1B). These data
indicate that matrix assembly site expression on vitronectinadherent cells can be up-regulated upon stimulation of Rhomediated signaling pathways.
Inhibition of 70-kDa Fragment Binding by Heparin-binding
Fragments of Vitronectin—The ability of LPA to stimulate 125Ilabeled 70-kDa fragment binding to vitronectin-adherent cells
suggests the possibility that the decreased basal level of matrix
assembly site expression on vitronectin-adherent cells may be
due to inhibitory signals generated upon cell adhesion to
vitronectin. Vitronectin is a modular glycoprotein that contains
domains that mediate binding to both cells and heparin (32). Cell
adhesion to vitronectin is mediated by the RGD sequence located
in the amino-terminal connecting sequence (32, 48 –50), while
vitronectin’s heparin-binding activity has been localized to a series of basic amino acid residues in the carboxyl-terminal hemopexin II domain (32, 51). To determine which regions of
vitronectin are important for regulating matrix assembly site
expression, intact vitronectin was subjected to limited proteolysis
with formic acid. Cell- and heparin-binding fragments were then
separated by heparin affinity chromatography (32). Cycloheximide-pretreated fibroblasts were seeded onto tissue culture wells
coated with either the 40-kDa cell-binding fragment of vitronectin or intact fibronectin in the absence and presence of various
concentrations of heparin-binding vitronectin fragments. As
shown in Fig. 2A, cells adherent to the cell-binding fragment of
vitronectin bound 125I-labeled 70-kDa fragment to a similar extent as cells adherent to intact fibronectin, suggesting that ligation of vitronectin binding integrins is permissive for the expression of matrix assembly sites. The addition of increasing amounts
of heparin-binding fragments of vitronectin to cells adherent to
either the cell-binding fragment of vitronectin or intact fibronectin resulted in a dose-dependent decrease in 125I-labeled 70-kDa
fragment binding (Fig. 2A). At the highest concentrations of
heparin-binding fragment tested, 125I-labeled 70-kDa fragment
binding to cells decreased to that observed on cells adherent to
intact vitronectin (Fig. 2A).
Adhesion of fibroblasts to vitronectin is mediated primarily
by the avb3 and avb5 integrins (52, 53). To determine whether
ligation of either avb3 or avb5 integrins results in the expression of matrix assembly sites, cycloheximide-pretreated cells
were seeded onto tissue culture wells coated with the vitronectin integrin receptor-specific peptide, GPenGRGDSP (50), or
the anti-avb3 (LM609) and avb5 (P1F6) monoclonal antibodies
in the absence or presence of 20 mg/ml heparin-binding fragments. Similar numbers of cells adhered to all wells, as assessed by crystal violet staining (data not shown). As shown in
Fig. 2B, ligation of integrin receptor avb3 or avb5 resulted in
levels of 125I-labeled 70-kDa fragment binding that were similar to the level observed on cells adherent to intact fibronectin.
The addition of vitronectin heparin-binding fragments decreased 125I-labeled 70-kDa fragment binding to cells adherent
to either GPenGRGDSP or to the anti-avb3 and -avb5 monoclonal antibodies to that observed on cells adherent to intact
vitronectin (Fig. 2B).
To further characterize the ability of the heparin-binding
region of vitronectin to inhibit the cell surface expression of
matrix assembly sites, intact vitronectin was preincubated
with increasing concentrations of heparin prior to coating onto
tissue culture wells. Following a 3-h incubation, unbound protein was removed, and wells were washed with PBS prior to the
seeding of cycloheximide pretreated fibroblasts. As demonstrated in Fig. 3, pretreatment of vitronectin with heparin
prevented the inhibitory effect of vitronectin on 125I-labeled

FIG. 2. Effect of heparin-binding fragments of vitronectin on
I-labeled 70-kDa fragment binding. A, cycloheximide-pretreated
fibroblasts were seeded onto tissue culture wells precoated with 10
mg/ml of the 40-kDa cell-binding fragment of vitronectin (hatched bars)
or intact fibronectin (solid bars) in the absence (0) or presence of
increasing concentrations of heparin-binding fragments of vitronectin.
Cells were also seeded onto intact vitronectin (open bars). B, cells were
seeded onto either vitronectin integrin receptor-specific peptides
(GPenGRGD), anti-integrin avb3 (LM609) or avb5 (P1F6) antibodies in
the absence (solid bars) or presence (hatched bars) of 20 mg/ml heparinbinding fragments of vitronectin. Cells were also seeded onto intact
fibronectin (Fn) or intact vitronectin (Vn). The 125I-labeled 70-kDa
fragment binding assay was performed as indicated in the legend to Fig.
1. Data are presented as 125I-labeled 70-kDa fragment bound per well 6
range (A) or S.E. (B).
125

70-kDa fragment binding and resulted in a dose-dependent
restoration of 125I-labeled 70-kDa fragment binding to levels
observed on fibronectin-adherent cells. Taken together, these
data indicate that ligation of either avb3 or avb5 integrins with
the RGD sequence of vitronectin is permissive for matrix assembly site expression, while the interaction of cells with a
region in or near the heparin-binding domain of vitronectin
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leads to a down-regulation of cell surface matrix assembly site
expression.
Localization of the Inhibitory Effect of Vitronectin on Matrix
Assembly Site Expression to the Heparin-binding Domain—To
more precisely localize the region of vitronectin responsible for
the inhibition of matrix assembly site expression, a recombinant GST fusion protein containing a 39-amino acid sequence
encompassing the heparin-binding domain of vitronectin (32,
51) was constructed and tested for its ability to alter 125Ilabeled 70-kDa fragment binding. As shown in Fig. 4, the
addition of increasing concentrations of the heparin-binding
domain of vitronectin to cells seeded onto fibronectin-coated
dishes resulted in a dose-dependent decrease in 125I-labeled
70-kDa fragment binding. This inhibitory effect was maximal
at 0.9 mM VnHBD and was specific to the heparin-binding domain of vitronectin. The addition of equal molar concentrations
of either GST alone or the heparin-binding domain of fibronectin (GST/FNIII12,13) (34, 54) to fibronectin-adherent cells had
no effect on 125I-labeled 70-kDa fragment binding (Fig. 4). In
addition, incubation of fibronectin-adherent cells with either
intact recombinant vitronectin or a recombinant vitronectin in
which the RGD sequence had been mutated to RGE (rVnRGE)
resulted in inhibition of 125I-labeled 70-kDa fragment binding
(Fig. 4). This inhibitory effect was maximal at 0.35 mM, providing further evidence that the inhibitory effect of vitronectin on
matrix assembly site expression is not due to integrin ligation
via the RGD sequence of vitronectin. Taken together, these
data indicate that the interaction of cells with the heparinbinding domain of vitronectin leads to a down-regulation of
matrix assembly site expression.
Vitronectin’s Heparin-binding Domain Inhibits Fibronectin
Polymerization—Upon binding of the amino-terminal region of
fibronectin to the cell surface, fibronectin accumulates in the
extracellular matrix in the form of disulfide-stabilized aggregates (45). As such, the ability of vitronectin’s heparin-binding
domain to down-regulate matrix assembly site expression indicates a role for the heparin-binding domain of vitronectin in
the regulation of fibronectin polymerization. To determine
whether the interaction of cells with the heparin-binding domain of vitronectin inhibits endogenous fibronectin matrix as-

FIG. 4. Effect of the heparin-binding domain of vitronectin on
I-labeled 70-kDa fragment binding. Cycloheximide-pretreated fibroblasts were seeded onto fibronectin-coated tissue culture wells and
allowed to adhere and spread for 45 min prior to the addition of GST/
VnHBD (f), recombinant vitronectin (●), recombinant VnRGE (M), GST/
FnIII12,13 (E), or GST (‚). Cells were incubated an additional 15 h at
37 °C. The 125I-labeled 70-kDa fragment binding assay was performed
as indicated in the legend to Fig. 1. Data are presented as the amount
of 125I-labeled 70-kDa fragment bound per well 6 S.E.
125

sembly, non-cycloheximide-treated fibroblasts were seeded
onto fibronectin-coated coverslips in the absence or presence of
either the heparin-binding domain of vitronectin (1.7 mM), the
heparin-binding domain of fibronectin (1.7 mM), or intact recombinant vitronectin (0.75 mM). These concentrations were
chosen to ensure maximum inhibition of 70-kDa fragment
binding (see Fig. 4). As demonstrated in Fig. 5A, control fibroblasts elaborated an extensive fibrillar fibronectin matrix. Similar fibrillar fibronectin staining was observed on cells that had
been incubated in the presence of GST/FnIII12,13 (Fig. 5B). In
contrast, treatment of cells with either the heparin-binding
domain of vitronectin (Fig. 5C) or intact recombinant vitronectin (Fig. 5D) markedly reduced the assembly of a fibronectin
matrix. These data demonstrate that the interaction of cells
with the heparin-binding domain of vitronectin inhibits endogenous fibronectin fibril formation and suggests a role for
vitronectin in the regulation of fibronectin matrix assembly.
Inhibition of Matrix Assembly Site Expression on b1 Null
Cells—Several recent studies indicate that fibronectin-binding
integrins other than a5b1, including a3b1 (55), “activated” avb3
(56), and “activated” aIIbb3 (22), can support fibronectin matrix
assembly. To determine whether the heparin-binding domain
of vitronectin also down-regulates non-b1 integrin-mediated
matrix assembly site expression, cycloheximide-pretreated b1null (GD25) and b1-transfected (GD25b1) cells were seeded
onto fibronectin-coated tissue culture wells in the absence or
presence of either intact vitronectin or the heparin-binding
domain of vitronectin. These cells, which lack b1-containing
integrin receptors due to a targeted knockout of the b1 gene
(57), have been shown to assemble a fibronectin matrix through
a mechanism that is thought to be dependent on the avb3
integrin (29). As shown in Fig. 6A, the addition of vitronectin to
either A1F fibroblasts, b1-null, or b1-transfected cells resulted
in a similar inhibition of 125I-labeled 70-kDa fragment binding.
Similar to the results obtained using A1F fibroblasts (Figs. 1B
and 4), the inhibitory effect of vitronectin on 125I-labeled 70kDa fragment binding to GD25 and GD25b1 cells was mediated
by the heparin-binding domain of vitronectin and was reversed
by treatment of cells with LPA (Fig. 6B). These studies indicate
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FIG. 3. Expression of 70-kDa binding sites on cells adherent to
heparin-treated vitronectin. Tissue culture wells were coated with
10 mg/ml untreated fibronectin (f) or vitronectin preincubated for 30
min with increasing concentrations of heparin (●). Wells were washed
with PBS, and cycloheximide-pretreated fibroblasts were seeded at 105
in DMEM/ITS12 with 20 mg/ml cycloheximide and allowed to adhere
and spread for 18 h. The 125I-labeled 70-kDa fragment binding assay
was performed as indicated in the legend to Fig. 1. Data are presented
as the amount of 125I-labeled 70-kDa fragment bound per well 6 S.E.
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that the interaction of cells with the heparin-binding domain of
vitronectin down-regulates both b1 and non-b1 integrin-mediated matrix assembly site expression.
The Heparin-binding Domain of Vitronectin Induces Actin
Filament Reorganization—Several studies have correlated
changes in the organization of the actin cytoskeleton with
changes in 70-kDa binding site expression and fibronectin matrix deposition (18, 21–23). To determine whether the heparinbinding domain of vitronectin induced changes in the distribution of actin filaments, serum-starved, non-cycloheximidetreated fibroblasts were seeded onto fibronectin-coated
coverslips in the absence or presence of the heparin-binding
domains of either vitronectin or fibronectin. Cells were allowed
to adhere and spread overnight, and actin was visualized by
staining fixed and permeabilized cells with fluorescein isothiocyanate-conjugated phalloidin. As shown in Fig. 7, in both
GST-treated cells (panel A) and GST/FnIII12,13-treated cells
(panel E), actin filaments were organized into thickly bundled
stress fibers commonly observed in fibronectin-adherent cells.
In contrast, treatment of cells with the heparin-binding domain
of vitronectin (3.4 mM) resulted in the organization of actin into
loose, broadly distributed microfilament nets (Fig. 7C). Under
these conditions, 100% of the cells exhibited changes in actin
organization. At lower concentrations of VnHBD (1.7 mM), approximately 50% of the cells exhibited readily visible changes
in actin microfilament organization (data not shown). Vinculin,
a protein that is highly concentrated at focal adhesions (58),
was clearly visible under all experimental conditions (Fig. 7, B,
D, and F).
Modulation of Cytoskeletal Interactions by the Heparin-binding Domain of Vitronectin—To further characterize the
vitronectin-induced changes in actin cytoskeletal organization,
the subcellular distributions of actin-associated proteins from
control and GST/VnHBD-treated cells were examined. As demonstrated in Fig. 8, treatment of cells with the heparin-binding

FIG. 6. Effect of vitronectin on 125I-labeled 70-kDa fragment
binding to b1-null cells. A, cycloheximide-pretreated A1F fibroblasts,
GD25, or GD25b1 cells were seeded at confluence onto fibronectincoated tissue culture wells and allowed to adhere and spread for 45 min
prior to the addition of either recombinant Vn (hatched bars) or an
equal volume of PBS (solid bars). The 125I-labeled 70-kDa fragment
binding assay was performed as indicated in the legend to Fig. 1. B,
GD25 (solid bars) or GD25b1 cells (hatched bars) were seeded onto
fibronectin-coated wells and treated with either the heparin-binding
domain of vitronectin (1VnHBD) or PBS. One hour prior to the assay,
some cells treated with GST/VnHBD were incubated with 2 mM LPA
(1LPA). Data are presented as 125I-labeled 70-kDa fragment bound per
well 6 S.E.

domain of vitronectin resulted in a significant decrease in the
level of a-actinin associated with the digitonin-soluble pool as
compared with levels observed in either control or GST/
FnIII12,13-treated cells. This decrease in soluble a-actinin was
accompanied by an increase in the level of a-actinin associated
with the digitonin-insoluble fraction (Fig. 8), suggesting that
stimulation of cells with the heparin-binding domain of
vitronectin triggers the redistribution of soluble a-actinin to
the actin cytoskeleton. To examine the distribution of other
actin-associated proteins, immunoblots were stripped and sequentially reprobed with antibodies directed against either
talin or vinculin (58). In contrast with the results obtained with
a-actinin (Fig. 8), treatment of cells with the heparin-binding
domain of vitronectin resulted in an increase in the level of
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FIG. 5. Effect of the heparin-binding domain of vitronectin on
endogenous fibronectin matrix assembly. Fibroblasts (105 in
DMEM/ITS12) were seeded onto coverslips precoated with 5 mg/ml of
fibronectin and allowed to adhere and spread for 45 min prior to the
addition of either PBS (A), GST/FnIII12,13 (B), GST/VnHBD (C), or recombinant vitronectin (D). Cells were incubated an additional 15 h at
37 °C. Cells were processed for immunofluorescence as indicated under
“Experimental Procedures.” Fibronectin fibrils were visualized using a
polyclonal anti-fibronectin antibody followed by an fluorescein isothiocyanate-labeled goat anti-rabbit antibody.
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in the soluble fractions obtained from either control or GST/
FnIII12,13- or GST/VnHBD-treated cells (Fig. 8). Taken together,
these data indicate that the interaction of fibronectin-adherent
cells with the heparin-binding domain of vitronectin stimulates
the organization of actin into microfilament nets concomitant
with the subcellular reorganization of specific actin-associated
proteins, including a-actinin and talin.
DISCUSSION

FIG. 8. Subcellular distribution of actin-associated proteins.
Serum-starved, non-cycloheximide-treated fibroblasts were resuspended in DMEM/ITS12 and seeded onto fibronectin-coated coverslips
in the presence of 3.4 mM of GST/VnHBD (VnHBD), GST/FnIII12,13
(FnIII12,13), or an equal volume of PBS (PBS). Following an 18-h incubation, cells were washed and extracted sequentially with digitonin (S)
and radioimmune precipitation (I) buffers. Fractions (10 mg/lane) were
resolved by electrophoresis and analyzed by immunoblotting with
monoclonal antibody specific for a-actinin. The blot was then stripped
and sequentially reprobed with monoclonal antibodies specific for talin
and vinculin. Results are representative of three separate experiments.

talin detected in the soluble fraction when compared with either control or GST/FnIII12,13-treated cells (Fig. 8). No significant differences in the levels of vinculin staining were observed
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FIG. 7. Effect of vitronectin’s heparin-binding domain on actin
organization. Serum-starved, non-cycloheximide-treated fibroblasts
were resuspended in DMEM/ITS12 at 2.5 3 104 cell/ml and seeded onto
fibronectin-coated coverslips in the presence of 3.4 mM of GST (A and B),
GST/VnHBD (C and D), or GST/FnIII12,13 (E and F). Following an 18-h
incubation, cells were fixed and permeabilized, and actin filaments
were visualized by staining with fluorescein isothiocyanate-phalloidin
(A, C, and E). Cells were co-stained for vinculin using an anti-vinculin
monoclonal antibody followed by a Texas Red-labeled goat anti-mouse
antibody (B, D, and F). Results are representative of three separate
experiments.

In the present study, we demonstrate that the interaction of
cells with the heparin-binding region of vitronectin inhibits
fibronectin matrix assembly site expression and fibronectin
deposition. The inhibitory effect of vitronectin’s heparin binding domain was seen in both b1-dependent and b1-independent
matrix assembly and could be overcome by treatment of cells
with LPA, an agent known to increase actin stress fiber formation (18, 24). Moreover, the interaction of fibronectin-adherent
cells with the heparin-binding domain of vitronectin resulted in
changes in the cytoskeletal organization of actin, as well as the
actin-binding proteins a-actinin and talin.
Several previous studies have demonstrated that modulation
of the actin cytoskeleton alters the ability of cells to assemble a
fibronectin matrix (18, 21–24). Our data indicate that inhibition of fibronectin matrix assembly by the heparin-binding
domain of vitronectin is associated with the formation of microfilamentous nets of actin and a marked redistribution of the
actin binding protein a-actinin to the cytoskeleton associated
pool. These cytoskeletal changes were specific for the heparinbinding domain of vitronectin, since differences were not observed upon treatment of cells with the heparin-binding domain of fibronectin. Our findings are in agreement with the
recent study by Zhang et al. (27), which shows that the downregulation of matrix assembly by cells adherent to vitronectin
is accompanied by changes in cell morphology. Previous studies
have demonstrated agonist-induced redistribution of cytoskeletal and signaling proteins in platelets (59, 60) and neutrophils
(61). Thus, it is possible that the redistribution of cytoskeletal
components upon treatment of cells with the heparin-binding
domain of vitronectin serves to localize or sequester signaling
enzymes involved in regulating matrix assembly.
Recently, it has been shown that LPA up-regulates expression of matrix assembly sites as well as fibronectin polymerization through the Rho-dependent activation of cellular contraction (23, 24). This finding suggests that one role for
organized actin in matrix assembly is to generate the contractile forces necessary for fibronectin polymerization. Earlier
studies have shown that in the absence of b1 integrins, b3
integrins can regulate matrix assembly (22, 29, 56). Vitronectin
inhibited matrix assembly site expression on b1 null cells,
suggesting that vitronectin is able to modulate fibronectin matrix assembly regulated by either b3 or b1 integrins. The ability
of LPA to overcome vitronectin inhibition of matrix assembly
suggests that the inhibitory signal from vitronectin may be
modulating a pathway important in maintaining levels of contractility sufficient to promote matrix assembly site expression.
In contrast, treatment of vitronectin-adherent cells with PMA,
an agent that does not increase fibroblast contractility (62), did
not result in an increase in matrix assembly site expression.
Recent studies have shown that vitronectin-mediated downregulation of 70-kDa binding sites can be partially reversed by
the expression of the b1 integrin and completely reversed when
cells expressing b1 are treated with LPA (27). Therefore, the
results from our study as well as the study by Zhang et al. (27)
are consistent with a mechanism in which maximum expression of fibronectin matrix assembly sites requires both b1 integrin and appropriate levels of cellular contractility.
The effect of vitronectin’s heparin-binding domain on fi-
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bronectin matrix assembly may be mediated by the avb5 integrin or by heparan sulfate proteoglycans. Vogel et al. (63) have
demonstrated by affinity chromatography that the avb5 integrin receptor binds to a peptide derived from the heparinbinding domain of vitronectin. This non-RGD-containing peptide is composed of 12 amino acids that are also contained
within the GST/VnHBD construct. Vitronectin has also been
shown to colocalize with heparan sulfate proteoglycans on endothelial cells (64). Removal of cell surface proteoglycans by
treatment with heparinase (36), b-D-xyloside (36), or sodium
chlorate (65) inhibits the binding of multimeric vitronectin to
cell surfaces, suggesting that the binding of vitronectin to cells
is mediated by an interaction between heparan sulfate proteoglycans and the heparin-binding domain of vitronectin.
Extrahepatic synthesis of vitronectin has been demonstrated
to be spatially and temporally regulated during development
and progression of certain tumors. Vitronectin synthesis is
increased in association with migrating cells (66, 67) and in
several tumors (68 –70). Our data support the hypothesis that,
in vivo, vitronectin may serve as a physiologic ligand responsible for the down-regulation of fibronectin matrix assembly
sites on fibroblasts at the tumor-stromal interface. Local synthesis of vitronectin would be expected to signal a decrease in
the levels of matrix assembly site expression by stromal fibroblasts. Since previous studies have demonstrated that decreased cell migration rates are associated with increased levels of polymerized fibronectin (7), dampening of matrix
assembly pathways by vitronectin would provide a mechanism
to facilitate tumor invasion of local connective tissue. The synthesis and deposition of vitronectin into the stroma of colorectal
adenocarcinoma by stromal fibroblasts (69) may reflect an autocrine mechanism that promotes fibroblast remodeling of the
stromal matrix. Recent studies have proposed that maintenance of cellular and tissue architecture may repress the tumor
phenotype (71). The role of vitronectin in promoting the matrix
remodeling that contributes to the disruption of local tissue
architecture associated with tumor progression remains an
important avenue of future investigation.
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